2021
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach C, Kahl B, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke J, Hirata J, Jiang Y, Paulson J, Chang Y, Musick L, Abrisqueta P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology 2021, 8: e891-e901. PMID: 34826412, DOI: 10.1016/s2352-3026(21)00311-2.Peer-Reviewed Original ResearchConceptsRecommended phase 2 doseRefractory follicular lymphomaPhase 2 dosePolatuzumab vedotinFollicular lymphomaAdverse eventsDay 1Dose escalationResponse rateRefractory diffuse large B-cell lymphomaCohort 3Treatment due to disease progressionCohort 2Diffuse large B-cell lymphomaEastern Cooperative Oncology Group performance statusCycles of induction treatmentDose-limiting toxicity eventsLarge B-cell lymphomaTyrosine kinase inhibitor treatmentComponent drugsPhase 1b/2 studyPhase 1b/2 trialComplete response rateDose-escalation phaseDose-limiting toxicity
2020
TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making
Bataillard E, Harris W, El-Galaly T, Kwan A, Henneges C, Paulson J, Nielsen T. TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-134904.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCurrent equity holderArea under the receiver operating characteristic curveAverage relative dose intensityCharlson Comorbidity IndexBone marrow lymphocytesR-CHOPAnti-CD20Progressive diseaseWithdrawal of cyclophosphamideAdverse eventsMarrow lymphocytesDiffuse large B-cell lymphoma patientsLong-term event free survivalTreatment of diffuse large B-cell lymphomaClinical trialsDose intensity of cyclophosphamideProportion of Th cellsTreated with R-CHOPF. Hoffmann-La RocheHigh risk of relapseLarge B-cell lymphomaAlternative therapiesR-CHOP treatmentRelative dose intensity